FDA approval for capivasertib: and our new collaboration opportunities for industry partners 17 Nov 2023 The US Food and Drug Administration (FDA) has approved the AKT inhibiting drug capivasertib, now given the brand name Truqap, as a breast cancer treatment. Henry French introduces other current opportunities for industry partners to work with ICR researchers, including in the discovery and development of cancer drugs, and asks – could any become the next capivasertib? Find out more Show/Hide
UK life sciences are thriving despite Covid-19 – but choppy waters lie ahead 15 Apr 2021 We’ve seen a surge in commercial investment in UK life sciences, driven by world-class interactions between academia and industry. But cuts to Government and charity funding for academic research could put that all at risk, says Angela Kukula, Director of Business and Innovation at the ICR. Find out more Show/Hide